William Murray, formerly group president of respiratory technologies for Viasys Healthcare, was named president of Applied Biosystems’ molecular biology division, joining the senior management team the company named in August as part of a strategic review that created a new divisional structure for the company (see BCW, 09/09/04).
Murray, who spent 17 years as an executive at Medtronic, takes over duties filled on an interim basis by Catherine Burzik, president of ABI. He takes over what was once the company’s flagship division, whose product portfolio includes: DNA sequencing, real-time PCR, microarrays, core PCR, and DNA synthesis.
Murray will be responsible for strategic planning and business development, research and development, product management, marketing, and program management, and will have direct responsibility for sales in North America, and will share responsibility with regional vice presidents for the division’s sales outside North America.
Murray was not available for comment prior to publication deadline.
The company said his experience in “large, complex and global businesses at Medtronic,” makes him “well-suited” for the position.
ABI is the leader in the DNA sequencing-technology market, but its revenues from sequencing are in decline. ABI had $116 million in DNA sequencing revenues for the three-month period ending Sept. 30, the company’s lowest revenue performance for at least the last 12 quarters, and down from $124.8 million for the same quarter in 2003. Still, the product line has been lucrative, accounting for 37 percent and 33 percent of the company’s revenues, respectively, for ABI’s FY ‘03 and FY ‘04. DNA sequencing revenues for FY ‘04 were $572.5 million, down from $631.7 million in FY ‘03.
The company also named Carl Hull as vice president and general manager for its real-time PCR systems and microarrays; Stephen Kondor as vice president and general manager for genetic analysis, filling the position formerly held by Deborah Smeltzer; and Peter Dansky as senior director and general manager for core PCR and DNA synthesis. They will have responsibility for business strategy and product line management, marketing strategies, and execution of new product development in their respective product and technology areas.
Hull joins ABI from a position as CEO of Applied Imaging. Previously he was vice president of marketing and business development at Ventana Medical Systems, and before that at Abbott Laboratories.
Kondor joins the company from Fisher Scientific, where he was vice president and general manger for its diagnostics unit. Previously, he worked for Becton Dickinson and Abbott Diagnostics.
Dansky joins the company from Arcturus Bioscience where he was vice president of marketing. Previously, he worked for Affymetrix and Millipore.
John Wareham, who last week announced his retirement as CEO of Beckman Coulter, joined the board of Pyxis Corp. of San Diego, the company said this week. Wareham, who will continue to serve as chairman of Beckman until April 7, is also a director of Steris, Wilson Greatbatch Technologies, and the Advanced Medical Technology Association.
Alex Moghadam was named as vice president for international operations for Zoll Medical, the company said last week. Moghadam joins the firm from Thermo Electron, where he headed the Bioscience Technologies division in Europe, Middle East, and Africa.